{"organizations": [], "uuid": "60644798b0dd64fa87bf07bf241265a763b0f2e5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-celldex-therapeutics-reports-q1-lo/brief-celldex-therapeutics-reports-q1-loss-per-share-0-84-idUSASC0A1F3", "country": "US", "domain_rank": 408, "title": "BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T15:11:00.000+03:00", "replies_count": 0, "uuid": "60644798b0dd64fa87bf07bf241265a763b0f2e5"}, "author": "", "url": "https://www.reuters.com/article/brief-celldex-therapeutics-reports-q1-lo/brief-celldex-therapeutics-reports-q1-loss-per-share-0-84-idUSASC0A1F3", "ord_in_thread": 0, "title": "BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-celldex therapeutics", "sentiment": "negative"}, {"name": "celldex therapeutics inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10, 2018 / 12:13 PM / Updated 7 minutes ago BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84 Reuters Staff\nMay 10 (Reuters) - Celldex Therapeutics Inc:\n* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS * Q1 REVENUE VIEW $2.3 MILLION — THOMSON REUTERS I/B/E/S\n* Q1 EARNINGS PER SHARE VIEW $-0.20 — THOMSON REUTERS I/B/E/S\n* CELLDEX - SEES CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AT MAR 31, PROCEEDS FROM SALES OF STOCK SUFFICIENT TO FUND OPERATIONS THROUGH 2020\n* CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $123.2 MILLION VERSUS $139.4 MILLION AS OF DEC 31, 2017 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-10T15:11:00.000+03:00", "crawled": "2018-05-10T15:26:28.008+03:00", "highlightTitle": ""}